Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-Hodgkin lymphoma
Pharma
BMS angles Breyanzi for another blood cancer
With another trial win, BMS is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types.
Angus Liu
Feb 10, 2025 9:50am
FDA approves Citius' Lymphir for cutaneous T-cell lymphoma
Aug 8, 2024 11:21am
AZ makes case for Calquence in another blood cancer type
Jun 17, 2024 11:25am
Inconsistent survival data dent Roche's Columvi win in 2L DLBCL
Jun 16, 2024 5:32pm
FDA spotlights timely cancer accelerated approval confirmation
Nov 15, 2023 8:20am
Abbvie, J&J pull 2 Imbruvica accelerated approvals
Apr 7, 2023 10:25am
